Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
Portfolio Pulse from
Kane Biotech has announced a change in its US distribution partner for its revyve™ Antimicrobial Wound Gel. BioStem Technologies has signed a letter of intent to acquire exclusive US distribution rights for revyve™ from ProgenaCare Global.
November 27, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioStem Technologies has signed a letter of intent to acquire exclusive US distribution rights for revyve™ Antimicrobial Wound Gel from ProgenaCare Global.
The acquisition of exclusive distribution rights for revyve™ could enhance BioStem Technologies' market presence and revenue potential in the US, likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80